ClinicalTrials.gg
Active, not recruitingNCT06450886Updated Jul 28, 2025

Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis

A Phase 2/3 interventional study of Ulviprubart (ABC008) in Inclusion Body Myositis (IBM), sponsored by Abcuro, Inc.. Active, not recruiting at 21 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-07-28.

Sponsored by Abcuro, Inc. · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
270
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Myositis, Inclusion Body with a site in United States — 4 open to participants now, 9 under way, 2 of them phase 3. Myositis, Inclusion Body · United States.

Planned enrollment
2nd of 27
270 · median 24
Started
2024
with 1 other
Phase 2/3
6 of 37
none open now
Registered
34th of 37
by date
Lead sponsor
2 of 37
Abcuro, Inc.

Among the 37 studies in Myositis, Inclusion Body with a site in United States, this one is the 2nd largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2024, is one of 6 in phase 2/3, and was the 34th registered.

Myositis, Inclusion Body

65 studies on the registry are indexed under Myositis, Inclusion Body; 10 are open to participants now.

Browse Myositis, Inclusion Body studies →

Open to participants now

4 of the 37 studies in Myositis, Inclusion Body with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Myositis, Inclusion Body studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Myositis, Inclusion Body with a site in United States, or all of them as a file.
02

Study summary

ABC008-IBM-202 is an open-label, multicenter study to evaluate the safety and efficacy of long-term administration of ulviprubart (ABC008) in subjects with IBM who have completed either Study ABC008-IBM-101 or Study ABC008-IBM-201. Subjects may be enrolled in this study if they meet study eligibility criteria and:

  • Have completed the Part 2 (Multiple Ascending Dose [MAD]) End of-Treatment (EOT) Visit in Study ABC008-IBM-101; subjects who continued further on into Part 3 of the study (MAD Extension) prior to enrolling in this study are also eligible; OR
  • Have completed the Week 80 Follow-up Visit in Study ABC008-IBM-201.
Read the detailed description

ABC008-IBM-202 is an open-label, multicenter study to evaluate the safety and efficacy of long-term administration of ulviprubart (ABC008) in subjects with IBM who have completed either Study ABC008-IBM-101 or Study ABC008-IBM-201. Subjects may be enrolled in this study if they meet study eligibility criteria and:

  • Have completed the Part 2 (Multiple Ascending Dose [MAD]) End of-Treatment (EOT) Visit in Study ABC008-IBM-101; subjects who continued further on into Part 3 of the study (MAD Extension) prior to enrolling in this study are also eligible; OR
  • Have completed the Week 80 Follow-up Visit in Study ABC008-IBM-201. Subjects will enter this study following their initial study such that dosing continues every eight weeks (Q8W) between the last dose in the initial study and the first dose in this long-term extension (LTE) Study IBM-202. Study subjects will continue to receive any ongoing concomitant medications from the initial study.

Subjects will be required to sign an informed consent form before undertaking any study-specific procedures or assessments. Screening is intended to be done at the final visit of the initial study, which will coincide with the Baseline (Day 1) Visit for this study; if this is not possible, the Baseline (Day 1) Visit for this study, including screening, may be conducted at a separate visit (provided it occurs within the visit window defined in Appendix 1 of the protocol). Subsequent study visits will occur every eight weeks until EOT at Week 156, or withdrawal from the study.

03

Conditions studied

  • Inclusion Body Myositis (IBM)
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Able to read, understand, and provide signed prior to the performance of any study-related procedures.

    2. Has participated in and completed either Study ABC008-IBM-101 or Study ABC008-IBM-201; completion of the prior study will be defined as completion of the Part 2 (MAD) EOT Visit in Study ABC008-IBM-101 (subjects may have continued into Part 3 [MAD Extension]) or completion of the Week 80 Follow-up Visit in Study ABC008-IBM-201.

    3. Demonstrated adequate compliance, in the opinion of the Investigator, with the study procedures during Study ABC008-IBM-101 or Study ABC008-IBM-201.

    4. Willing and able to comply with the requirements of the protocol, including traveling to the site for study-related assessments and SC injections of ulviprubart.

    5. Women of (WOCBP) and male subjects with female partners who are WOCBP (based on sex assignation at birth) must agree to use highly effective (\< 1% failure rate) for the duration of the study through 180 days after EOT/ETV.

    6. WOCBP (based on sex assignation at birth) must have a negative urine pregnancy test at the Baseline (Day 1) Visit.

    7. Male subjects (based on sex assignation at birth) must refrain from sperm donation for the duration of the study through 180 days after EOT/ETV.

Exclusion criteria

Exclusion Criteria:

  • 1. Has an unresolved AE or a clinically significant finding on a clinical laboratory test, , or physical examination during Study ABC008-IBM-101 or Study ABC008 IBM-201 that, in the Investigator's opinion, would limit the subject's ability to participate in or comply with this study.

    2. Participation in another drug study (other than Study ABC008-IBM-101 or Study ABC008-IBM-201) within 30 days prior to the Baseline (Day 1) Visit or five times the half-life of the investigational drug, whichever is longer.

    3. Is not willing or able to comply with the restrictions regarding the use of prohibited medications throughout the study.

    4. Women who are pregnant, lactating, or who plan to become pregnant or initiate lactation during the study.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    Ulviprubart (ABC008) 2.0 mg/kg SC

    All eligible subjects, regardless of treatment assignment or dose level in their initial study, will be administered ulviprubart at a dose of 2.0 mg/kg via subcutaneous (SC) injection Q8W.

    Drug: Ulviprubart (ABC008)

Interventions

  • DrugUlviprubartStudies of UlviprubartUlviprubart pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All eligible subjects, regardless of treatment assignment or dose level in their initial study, will be administered ulviprubart at a dose of 2.0 mg/kg via subcutaneous (SC) injection Q8W.

06

What researchers measure

Primary outcomes

  1. Primary Endpoint

    The primary endpoint for the study will be the incidence, type, and severity of treatment-emergent adverse events (TEAEs). Safety as assessed by the incidence, type and severity of Treatment Emergent Adverse Events (TEAEs)

    Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]

Secondary outcomes

  1. Treatment Emergent Serious Adverse Events (TEASAEs)

    Incidence, type, and severity of treatment-emergent serious adverse events (TESAEs)

    Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]

  2. Treatment Emergent Adverse Events (TEAEs) onset within 24 hours of Study Medication Administration.

    Incidence of TEAEs leading to study medication or study discontinuation

    Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]

  3. Adverse Events of Special Interest (AESI)

    Incidence of Adverse events of special interest (AESIs)

    Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]

  4. Change from baseline standard laboratory parameters (Hematology)

    Incidence of clinically significant changes in standard laboratory parameters (Hematology)

    Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]

  5. Change from baseline in standard laboratory parameters (Chemistry)

    Incidence of clinically significant changes from baseline in standard laboratory parameters (Chemistry)

    Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]

  6. Change from baseline in standard laboratory parameters (Coagulation)

    Incidence of clinically significant changes from baseline standard laboratory parameters (Coagulation)

    Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]

  7. Inclusion Body Myositis Functional Rating Scale (IBMFRS)

    Mean change from Baseline (Day 1) in IBMFRS over the duration of the study

    Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]

  8. Manual Muscle Test 12 (MMT 12)

    Mean change from Baseline (Day 1) in MMT 12 over the duration of the study

    Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]

  9. Change from baseline in standard vital signs (respiratory rate)

    Incidence of clinically significant changes in vital signs (respiratory rate)

    Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]

  10. Change from baseline in standard vital signs blood pressure

    Incidence of clinically significant changes in standard vital signs blood pressure (Systolic and diastolic) blood pressure)

    Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]

  11. Change from baseline in standard vital signs (temperature)

    Incidence of clinically significant changes in standard vital signs (temperature)

    Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]

  12. Change from baseline in standard vital signs (pulse rate)

    Incidence of clinically significant changes in standard vital signs (pulse rate)

    Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]

  13. Counts of absolute and KLRG1+ lymphocytes by flow cytometry.

    Blood samples will be collected for immunophenotyping. Counts of absolute and KLRG1+ lymphocytes and other lymphocyte subsets will be performed by flow cytometry.

    Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]

  14. Presence and titer of antidrug antibodies (ADA)

    The incidence and titers of ADAs to ulviprubart will be evaluated in blood samples

    Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]

  15. Serum concentration of ulviprubart

    Individual and mean serum concentration time profiles will be presented graphically using nominal time points.

    Time frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]

07

Study locations

21 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Jan 2029, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2024
First posted
Jun 10, 2024
StartActual
Oct 21, 2024
Primary completionEst.
Jan 2029
CompletionEst.
Apr 2029
Last update
Jul 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06450886
Lead sponsor
Abcuro, Inc.
Responsible party
Sponsor
First posted
Jun 10, 2024
Start date
Oct 21, 2024
Primary completion
Jan 2029 (estimated)
Completion
Apr 2029 (estimated)
Last update
Jul 28, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ulviprubart

Start the discussion